Microfluidic Devices for Manufacture of Therapeutic Extracellular Vesicles: Advances and Opportunities
Journal of Extracellular Vesicles · 2025-07 · 14 (7)
DOI: 10.1002/jev2.70132 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 24.07.2025. Verfasst von Amin Hassanzadeh-Barforoushi und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Natural Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Extracellular Vesicles, Lab-On-A-Chip Devices, Microfluidics. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Council NSW, Australian Government and the CRC-P.
Abstract (Originalsprache)
Extracellular vesicles (EVs) are emerging as promising candidates in therapeutic applications due to their unique ability to mediate intercellular communication and deliver biological cargo. With increasing interest in EV‐based therapies, the development of scalable, cost‐effective and regulatory‐compliant production methods is critical. Microfluidic platforms offer transformative potential in EV manufacturing, providing precise control over production conditions, enhanced purity and seamless integration with quality control systems. This review highlights the advantages of microfluidic technologies in EV production, including fine‐tuning of shear stress to optimise yield, advanced purification strategies that achieve high recovery and purity, and on‐chip capabilities for EV loading and surface modification. Key challenges such as scaling up production while maintaining sterility, controlling EV release after immunoaffinity capture, and addressing clogging and fouling in microfluidic devices are discussed alongside emerging solutions. Additionally, the integration of AI‐driven automation and real‐time monitoring, as well as personalised EV manufacturing, is explored as pivotal innovations. Future directions emphasise the potential of combining size‐ and affinity‐based methods for EV isolation and aligning microfluidic technologies with regulatory requirements to accelerate clinical translation. Therefore, we believe microfluidics platforms for EV isolation hold immense potential to redefine EV manufacturing by enabling scalable, reproducible and high‐quality production systems essential for therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- School of Natural Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, Australia.
- VivaZome Therapeutics Pty Ltd, Melbourne, VIC, Australia.
ORCID-Profile: Amin Hassanzadeh-Barforoushi, Ella L Johnston, Yuling Wang
Förderung
- Cancer Council NSW
- Australian Government and the CRC-P
Zitieren
APA
Hassanzadeh-Barforoushi, A., Sango, X., Johnston, E. L., Haylock, D., & Wang, Y. (2025). Microfluidic Devices for Manufacture of Therapeutic Extracellular Vesicles: Advances and Opportunities. Journal of Extracellular Vesicles, 14(7). https://doi.org/10.1002/jev2.70132
Vancouver
Hassanzadeh-Barforoushi A, Sango X, Johnston EL, Haylock D, Wang Y. Microfluidic Devices for Manufacture of Therapeutic Extracellular Vesicles: Advances and Opportunities. Journal of Extracellular Vesicles. 2025;14(7). doi:10.1002/jev2.70132
BibTeX
@article{HassanzadehBarforoushi2025,
author = {Hassanzadeh-Barforoushi, Amin and Sango, Xenia and Johnston, Ella L and Haylock, David and Wang, Yuling},
title = {Microfluidic Devices for Manufacture of Therapeutic Extracellular Vesicles: Advances and Opportunities},
journal = {Journal of Extracellular Vesicles},
year = {2025},
volume = {14},
number = {7},
doi = {10.1002/jev2.70132}
}
EUVIMED